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background: Methadone-associated sudden arrhythmic death is due to polymorphic ventricular fibrillation arising from QT prolongation 
associated with perturbations in the delayed potassium rectifier current. Risk for QT prolongation has been independently associated with both 
increased formation of the methadone metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidene (EDDP) and with the presence of the 
CYP2C19*2 variant (rs4244285). Here we examine the association between EDDP, CYP2C19*2 variant and QT prolongation.
methods: The prospective observational study, MEMORIES (MEthadone MOnitoRIng for Adverse Events Study), enrolled 25 consecutive, consenting 
individuals initiating methadone maintenance treatment. Following oral methadone, peak (4-hr) and trough (24-hr) blood samples were obtained 
on days 1, 7 and 21. Plasma was analyzed for methadone and EDDP by liquid chromatographic-electrospray ionization-tandem mass spectrometry. 
Corrected (Bazett’s) QT (QTc) was measured from 12-lead ECGs obtained prior to dose one and at 21 days. Genotyping for rs4244285 employed 
Taqman real-time polymerase chain reaction. T tests were used for analyses.
results: No association was seen between CYP2C19 genotype and plasma methadone concentration. Individuals carrying the CYP2C19*2 variant 
as compared with wild type (wt) had higher combined (all days) peak (43.5 vs 26.6 ng/mL, p=0.02) and trough (22.1 vs 13.7 ng/mL; p=0.02) 
plasma EDDP concentrations. Dose-corrected EDDP was higher for *2 variant carriers vs wt for trough measurements at all time points (1.49 to 1.99 
fold; p=0.05-0.005) and for peak measurements at days 7 and 21 (1.78 and 1.44 fold; p=0.009 and p=0.015). The peak and trough effects were 
significant for both EDDP enantiomers (days 7 and 21; p < 0.006-0.017). Of 25 participants 17 experienced increased QTc (mean, 39.9 ms). The 
mean increase was significantly higher for *2 variant carriers (n=5) than for wt (n=12) (55.3±32.5 msec vs 31.5±21.0 msec, p=0.039).
conclusions: A mechanistic association between methadone-associated QT prolongation, CYP2C19 genotype and EDDP concentration may exist; 
direct demonstration of this association is needed.
